24-Month Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis Pigmentosa Associated With Usher Syndrome
NCT ID: NCT07290530
Last Updated: 2025-12-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
PHASE3
80 participants
INTERVENTIONAL
2026-06-30
2028-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Does NPI-001 slow down the loss of photoreceptors? What medical problems do participants have when taking NPI-001? Researchers will compare NPI-001 to a placebo (a look-alike substance that contains no drug) to see if NPI-001 works to preserve vision.
Participants will:
Take NPI-001 or a placebo twice a day, every day for 24 months Visit the clinic 9 times for checkups and tests
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
NPI-001
NPI-001 tablet, BID
N-acetylcysteine amide
N-acetylcysteine amide (NPI-001) tablets (250 mg), taken BID
Placebo
Placebo tablet, BID
Placebo
Placebo tablets, BID
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
N-acetylcysteine amide
N-acetylcysteine amide (NPI-001) tablets (250 mg), taken BID
Placebo
Placebo tablets, BID
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Diagnosed with Usher syndrome.
3. EZ zone width ≥ 500 microns, which includes the fovea in each eye at Visit 1 (Screening).
4. All edges of the EZ area in both eyes can be visualized at Visit 1 (Screening).
5. Have at least 20 detectable points on the MAIA grid in at least one eye at the Screening and Baseline visits (same eye for both visits).
5\. On stable dose of medications associated with other conditions for at least one month.
6\. Both female participants of childbearing potential and male participants able to father children must have (or have a partner who has) had a bilateral oophorectomy, hysterectomy or bilateral salpingectomy; must abstain from intercourse; or must agree to practice 2 acceptable methods of contraception throughout the course of the study and 4 weeks after the last visit. Acceptable methods of contraception include hormonal contraception (i.e., birth control pills, injected hormones, dermal patch or vaginal ring), intrauterine device, barrier methods (diaphragm, condom) with spermicide, tubal ligation, and vasectomy.
Exclusion Criteria
2. Intraocular surgery within the last two months or capsulotomy within the last month.
3. Current or history of uveitis, Coat's disease, diabetic retinopathy, glaucoma, herpes simplex of the eye, or currently has a cataract that prevents visualization of the posterior pole.
4. Likely to require cataract surgery within the next 12 months.
5. Unstable fixation during microperimetry in either eye at either Screening or Baseline visits.
6. Use of any other investigational new drug, or participation in another clinical trial within 12 weeks before the start of study treatment.
7. Use of N-acetylcysteine containing products in the previous 30 days prior to the baseline visit or unwilling to refrain from such supplements for the duration of the study.
8. Chronic liver or kidney disease, cystic fibrosis, severe asthma, or chronic obstructive pulmonary disease (COPD), history of thrombocytopenia not due to a reversible cause, or other blood dyscrasia.
9. Suspected liver dysfunction determined by having alanine aminotransferase (ALT), aspartate aminotransferase (AST), or bilirubin values \> 1.5 X the upper limit of normal (ULN) at screening.
10. Platelet or hemoglobin values \< 100 at screening.
11. History of known sensitivity to N-acetylcysteine or similar thiol compounds or any ingredients of NPI-001.
12. History of hypersensitivity to any medication or food resulting in systemic symptoms.
13. History of cancer (other than non-melanoma skin cancer) diagnosed or requiring treatment within the past 2 years.
14. Pregnant women or women planning to become pregnant in the next 25 months or men with partners planning to become pregnant in the next 25 months.
15. Lactating women who are breast-feeding.
16. Potential participant lives in the same household as a current participant in this study.
17. Subjects who are willing or unable to refrain from donation of blood from 30 days prior to Screening, plasma from 2 weeks prior to Screening, or platelets from 6 weeks prior to Screening until 56 days following the last study drug dose administered.
18. Inability to provide blood samples, including difficulty with venous access.
19. Any reason, in the opinion of the Principal Investigator, the participant should not participate.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Nacuity Pharmaceuticals, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
C-24-01
Identifier Type: -
Identifier Source: org_study_id